← Leaderboards
Oliver Jonas
Brigham And Women'S Hospital
$9,092,029
Attributed
$13,920,781
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,920,781 · 7
By mechanism
R01$11,140,829 · 5
R37$2,381,044 · 1
R21$398,908 · 1
Top collaborators
- Nobuhiko Hata5 shared
- Adam S Kibel5 shared
- Guillermo J. Tearney5 shared
- Pier Paolo Peruzzi3 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Clare M Tempany$31,151,323
- William M Wells$5,899,370
- Nobuhiko Hata$5,976,509
- Darwin Lewis Conwell$4,388,487
- Zhe Li$8,930,965
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorMicrodeviceResponsePhenotypeTechnologyPharmaceutical PreparationsTissuesDevicesMeasurementMetabolomicsBiologicalImmunologicsMalignant NeoplasmsClinical ResearchPathologyPredicting ResponseSelection For TreatmentsMinimally InvasiveIn SituImageChemotherapyIn VivoMetabolismIndividual Patient
Grant awards (27)
Using implantable microdevices for deep phenotyping of multiple drug responses in brain tumor patients$714,942
R01 · FY2025 · CA · contact PI
Development and optimization of highly effective treatments in patients with head and neck cancer using in situ implantable microdevices$703,540
R01 · FY2025 · CA · contact PI
Dynamic µOCT for cellular tissue phenotyping$621,021
R01 · FY2025 · CA
Using implantable microdevices for deep phenotyping of multiple drug responses in brain tumor patients$682,907
R01 · FY2024 · CA · contact PI
Dynamic µOCT for cellular tissue phenotyping$587,199
R01 · FY2024 · CA
Using implantable microdevices for deep phenotyping of multiple drug responses in brain tumor patients$746,821
R01 · FY2023 · CA · contact PI
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$658,228
R01 · FY2023 · CA · contact PI
Dynamic µOCT for cellular tissue phenotyping$606,936
R01 · FY2023 · CA
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement$419,469
R37 · FY2023 · CA · contact PI
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$667,356
R01 · FY2022 · CA · contact PI
Dynamic µOCT for cellular tissue phenotyping$596,805
R01 · FY2022 · CA
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement$428,028
R37 · FY2022 · CA · contact PI
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices$386,374
R01 · FY2022 · CA · contact PI
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$686,566
R01 · FY2021 · CA · contact PI
Dynamic µOCT for cellular tissue phenotyping$619,861
R01 · FY2021 · CA
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices$386,374
R01 · FY2021 · CA · contact PI
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement$381,309
R37 · FY2021 · CA · contact PI
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$675,388
R01 · FY2020 · CA · contact PI
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices$386,374
R01 · FY2020 · CA · contact PI
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement$381,309
R37 · FY2020 · CA · contact PI
Clinical Evaluation of an Implantable Lab-in-a-patient microdevice that measures in-situ response to therapies in advanced ovarian cancer$215,172
R21 · FY2020 · CA · contact PI
Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients$673,221
R01 · FY2019 · CA · contact PI
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices$374,782
R01 · FY2019 · CA · contact PI
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement$369,870
R37 · FY2019 · CA · contact PI
Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement$401,059
R37 · FY2018 · CA · contact PI
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices$366,134
R01 · FY2018 · CA · contact PI
Clinical Evaluation of an Implantable Lab-in-a-patient microdevice that measures in-situ response to therapies in advanced ovarian cancer$183,736
R21 · FY2018 · CA · contact PI